Alvarenga Daniel Gomes de, Escalda Patrícia Maria Fonseca, Costa Alexandre Sylvio Vieira da, Monreal Maria Tereza Ferreira Duenhas
Departamento de Patologia, Universidade Vale do Rio Doce, Governador Valadares, MG.
Rev Soc Bras Med Trop. 2010 Mar-Apr;43(2):194-7. doi: 10.1590/s0037-86822010000200017.
Visceral leishmaniasis is a public health problem, with lethality reaching 10%. The recommended drug treatment is methylglucamine antimoniate. This study aimed to evaluate drug use for cases of visceral leishmaniasis treated at the Infectology Clinic of the Campo Grande University Hospital Center, State of Mato Grosso do Sul.
To collect data, we examined the medical records of 76 patients with a diagnosis of visceral leishmaniasis treated at this Infectology Clinic.
The medical files of 76 patients (56 men and 20 women; 28.9%) showed comorbidities. The first choice drug for 88.2% of the patients was N-methylglucamine antimoniate, with a fatal outcome for 18.4%. Survival analysis showed a statistically significant difference between patients with and without comorbidities (p <0.0001) and with comorbidities who used Glucantime (p < 0.0009). The fatality rate of 18.4% indicates the low efficiency of the healthcare measures used.
The results suggest that the prognosis becomes poor when associated with the presence of comorbidities, and that the treatment needs to be carefully administered to minimize mortality.
内脏利什曼病是一个公共卫生问题，致死率达10%。推荐的药物治疗是葡甲胺锑酸盐。本研究旨在评估南马托格罗索州大坎普大学医院中心传染病诊所治疗的内脏利什曼病病例的用药情况。
为收集数据，我们查阅了该传染病诊所76例诊断为内脏利什曼病患者的病历。
76例患者（56名男性和20名女性；28.9%）的病历显示有合并症。88.2%的患者首选药物是葡甲胺锑酸盐，其中18.4%的患者死亡。生存分析显示，有合并症和无合并症患者之间（p<0.0001）以及使用葡酸锑钠的合并症患者之间（p<0.0009）存在统计学显著差异。18.4%的死亡率表明所采用的医疗措施效率低下。
结果表明，合并症会使预后变差，需要谨慎给药以降低死亡率。
